title: Therapeutic options for HIV-associated lymphomas.
abstract: BACKGROUND
  The clinical features and natural history of HIV-associated lymphomas differ greatly from those observed in the general population. The failure to improve outcomes with treatment intensification indicates the need for the introduction of new therapeutic options.
  
  
  METHODS
  This review summarizes reports from 1995 to the present which focus on the treatment strategies and their prognostic relevance in the setting of HIV-associated lymphomas.
  
  
  RESULTS
  The identification of prognostic factors in rare tumors such as HIV-associated lymphomas is going to require the establishment of multi-institutional and cooperative group-supported tissue banks. The rarity of primary effusion lymphomas and plasmablastic lymphomas of the oral cavity type makes large prospective studies difficult and challenges the feasibility of defining therapy specific for a given subpopulation of patients.
  
  
  CONCLUSIONS
  HIV-associated lymphomas still represent a relevant field of clinical research. Standard methodologies for therapy in this patient population have yet to be established. However, rituximab plus chemotherapy should be offered to the majority of patients with HIV infection and diffuse large B-cell lymphomas; and the feasibility of intensive aggressive chemotherapy regimens has been successfully tested in HIV-associated Burkitt's lymphomas.
authors: Department of Medical Oncology, Centro di Riferimento Oncologico Aviano, Istituto Nazionale Tumori, Italy.
authors: Michele
authors: M
authors: Spina
authors: Annunziata
authors: A
authors: Gloghini
authors: Umberto
authors: U
authors: Tirelli
authors: Antonino
authors: A
authors: Carbone
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000639:trends; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000188:drug therapy; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D016483:Lymphoma, AIDS-Related / Q000150:complications* / Q000188:drug therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications / Q000188:drug therapy; D011719:Pyrazines / Q000627:therapeutic use; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D001897:Boronic Acids; D011719:Pyrazines; D000069283:Rituximab; D000069286:Bortezomib; C527517:ofatumumab